"The market for vitamin K2 as MK-7 is clearly expanding as the scientific evidence of its ability to promote bone and cardiovascular health continues to accumulate," said Hogne Vik, CEO, NattoPharma. “As vitamin K2 awareness has been rapidly growing, NattoPharma has been fielding an influx of inquiries. Glanbia Nutritionals' broad and deep customer base will benefit from this vital new offering, which will further enhance NattoPharma’s U.S. presence."
NattoPharma's MenaQ7® PURE is produced in a European pharmaceutical manufacturing facility and is fully validated by numerous human clinical studies, as well as in-vivo and in-vitro research.